Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.

@article{Kim2009RationalCT,
  title={Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.},
  author={S Kim and Deepak Rai and Morgan R. McKeller and Ricardo Aguiar},
  journal={Blood},
  year={2009},
  volume={113 24},
  pages={6153-60}
}
Identification of rational therapeutic targets is an important strategy to improve the cure rate of diffuse large B-cell lymphoma (DLBCL). We previously showed that inhibition of the phosphodiesterase 4B (PDE4B) unleashes cyclic-AMP (cAMP) inhibitory effects toward the PI3K/AKT pathway and induces apoptosis. These data raised important considerations as to which upstream regulators mediate cAMP inhibition of PI3K/AKT, and how identifying this signaling route could be translated into clinical… CONTINUE READING
17 Extracted Citations
29 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 17 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 29 references

Tamatinib fosdium (TAMF), an oral SYK inhibitor, has significant clinical activity in B-cell nonHodgkin’s lymphoma (NHL)

  • J Friedberg, J Sharman, J Schaefer-Cutillo
  • Ann Oncol
  • 2008

Similar Papers

Loading similar papers…